New Era of Remote Working Calls for Modern Security Mindset, Finds Thales Global Survey of IT Leaders
COVID-19 quickly ushered in the era of remote work, introducing new risks that IT professionals are struggling to manage with existing security tools, according to a new Thales study. Six in 10 respondents said traditional security tools such as VPNs are still the primary vehicle for employees accessing applications remotely -- likely the reason why almost half (44%) were not confident that their access security systems could scale effectively to secure remote work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005014/en/
These are among the key insights from the 2021 Thales Access Management Index, a global survey of 2,600 IT decision makers, commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, to better understand the new security risks and challenges caused by the rise of remote working and cloud transformation caused by the COVID-19 pandemic.
Last year saw a surge in cybercrime exploiting the various aspects of the COVID-19 pandemic and the shift to remote work, with ransomware attacks soaring by 150%.1 The Thales survey found the pandemic’s effects have had a significant impact on security infrastructure, particularly on access management and authentication frameworks, pushing organisations to adopt modern security strategies like Zero Trust to support the demands of a more mobile and remote workforce.
Era of Remote Working – Concerns Catalyse Change
According to the index, respondents have many different systems deployed for remote access. When asked about the technologies that were in place, VPN was the most common, with 60% of IT professionals identifying the capability. Virtual Desktop Infrastructure, cloud-based access and Zero Trust network access/software defined perimeter (ZTNA/SDP) closely followed. However, when asked what new access technologies respondents were planning to deploy due to the pandemic, nearly half (44%) indicated ZTNA/SDP was the top technology choice.
Thales also explored respondents’ plans to move beyond traditional VPN environments, and found that nearly 40% expect to replace their VPN with ZTNA/SDP, while 38% expect to move to a Multi-Factor Authentication (MFA) solution. This confirms the need for more modern, sophisticated authentication capabilities is driving change in many organisations and is perceived as a key enabler of Zero Trust security.
“Seemingly overnight, remote access went from being an exception to the default working model for a large swath of employees. As a result, businesses are navigating a volatile and complex world, and adopting a Zero Trust model of cybersecurity will enable them to continue to conduct operations safely amidst the uncertainty,” said Francois Lasnier, vice president of Access Management solutions at Thales. “One of the core barrier businesses face when starting their Zero Trust journey is the balance between locking down access without interrupting workflow. People require access to sensitive data in order to work and collaborate and businesses leaders will need to ensure that a drop in productivity doesn’t become an unwanted side effect. The research shows that IT professionals increasingly see access management and modern authentication capabilities as key component in achieving a Zero Trust model.”
Room to Grow with Zero Trust
The Thales report found that Zero Trust models are the solution of choice for respondents seeking to improve access environments, yet many are still in the early stage of adoption.
According to the research, less than a third (30%) of the respondents claim to have a formal strategy and have actively embraced a Zero Trust policy. Additionally, almost half (45%) are either planning, researching or considering a Zero Trust strategy. Surprisingly, less than a third (32%) of the respondents indicated that Zero Trust shapes their cloud security strategy to a great extent.
Access Security Needs to Adapt to Deal with Dynamic Workplaces
A silver lining of the pandemic-driven rush to remote working is the acceleration of improved approaches to access security. Thales found that 55% of respondents currently have adopted two-factor authentication within their organisations. Regionally, there was notable variation, with the UK leading (64%), followed by the U.S. (62%), APAC (52%) and LATAM (40%). These varying degrees of adoption may be due to the level at which better access management is prioritised in security investments.
Yet, despite the well-known limitations of passwords, investment in MFA still trails other security tools like firewalls, endpoint security, SIEM and email security. Remote access users are still the main use case for MFA adoption (71%). One-third of respondents that have adopted MFA use more than three different authentication tools, signaling the need for a more unified approach to access management in the future.
“Security tools and approaches need to adapt to better support the era of remote working,” said Eric Hanselman, chief analyst at 451 Research, part of S&P Global Market Intelligence. “The shift towards a Zero Trust model, along with increasing use of modern authentication technologies, like adaptive and multifactor authentication (MFA), will improve organisations’ security posture. This will be an exciting space to watch as businesses continue to deal with dynamic workplace environments.” 2
Thales and 451 Research will discuss the global findings in more detail during its upcoming Trusted Access Summit on 5 October 2021. To join, please visit the registration page.
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
Group-IB Ransomware Uncovered 2020-2021
2 Quote from Thales 2021 Global Access Management Index
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Thales, Media Relations
+33 (0)6 44 12 16 35
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 16:34:00 EEST | Press release
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 07:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021
Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 21:46:00 EEST | Press release
Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli
Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 20:01:00 EEST | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li
Wipro Announces Co-innovation Space with Google Cloud17.9.2021 16:32:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou
Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 16:00:00 EEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 15:00:00 EEST | Press release
BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom